ELTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Elicio Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.55−0.01 (-0.64%)
Close on Oct 19, 2026
- Market cap
- $29.83M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$7.80 (−83.42%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $29.83M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 3.76
- Dividend yield
- –
- Free cash flow yield
- -123.93%
Fundamentals
- Net income
- -$37.84M
- EPS, diluted
- -$2.18
- Free cash flow
- -$36.97M
- Book value per share
- $0.41
- Diluted shares
- 19M
Seven years at a glance
Fiscal years 2019 to 2025 and trailing twelve months, USD
Revenue
–
Gross profit
–
Operating income
-$37.92M
Net income
-$37.84M
EPS, diluted
-$2.18
Free cash flow
–
Reported periodTrailing twelve months